Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines

References

• D'Souza MP, Yang OO. Adenovirus vectors as HIV-1 vaccines: where are we? What next? AIDS 2015; 29:395-400; PMID:25630039; https://doi.org/10.1097/QAD.0000000000000548
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-71; PMID:17109337; https://doi.org/10.1086/508748
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65; PMID:15688278; https://doi.org/10.1086/428404
   PubMed Web of Science ®Google Scholar
• Kong WP, Wu L, Wallstrom TC, Fischer W, Yang ZY, Ko SY, Letvin NL, Haynes BF, Hahn BH, Korber B, et al. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 2009; 83:2201-15; PMID:19109395; https://doi.org/10.1128/JVI.02256-08
   PubMed Web of Science ®Google Scholar
• Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, Bett AJ, Casimiro DR, Shiver JW, DiNubile MJ, et al. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin Vaccine Immunol 2009; 16:1285-92; PMID:19605598; https://doi.org/10.1128/CVI.00144-09
   PubMed Web of Science ®Google Scholar
• Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2011; 11:321-30; PMID:21557723; https://doi.org/10.2174/156652311796150354
   PubMed Web of Science ®Google Scholar
• Wan Y, Wu L, Liu L, Xu J, Liu Y, Shao Y. Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. Vaccine 2007; 25:4949-59; PMID:17350736; https://doi.org/10.1016/j.vaccine.2007.01.118
   PubMed Web of Science ®Google Scholar
• McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-905; PMID:19012957; https://doi.org/10.1016/S0140-6736(08)61592-5
   PubMed Web of Science ®Google Scholar
• Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Eng J Med 2013; 369:2083-92; PMID:24099601; https://doi.org/10.1056/NEJMoa1310566
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93; PMID:19012954; https://doi.org/10.1016/S0140-6736(08)61591-3
   PubMed Web of Science ®Google Scholar
• Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 2013; 31:3502-18; PMID:23707164; https://doi.org/10.1016/j.vaccine.2013.05.018
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Eng J Med 2012; 366:1275-86; PMID:22475592; https://doi.org/10.1056/NEJMoa1113425
   PubMed Web of Science ®Google Scholar
• Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, Cashin-Cox M, Naarding M, Clark L, Fernandez N, et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PloS One 2012; 7:e41936; PMID:22870265; https://doi.org/10.1371/journal.pone.0041936
   PubMed Web of Science ®Google Scholar
• Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 2013; 207:240-7; PMID:23125444; https://doi.org/10.1093/infdis/jis670
   PubMed Web of Science ®Google Scholar
• Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, Kostense S, Penders G, Helmus N, Koudstaal W, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77:8263-71; PMID:12857895; https://doi.org/10.1128/JVI.77.15.8263-8271.2003
   PubMed Web of Science ®Google Scholar
• Appaiahgari MB, Pandey RM, Vrati S. Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines. Clin Vaccine Immunol 2007; 14:1053-5; PMID:17596429; https://doi.org/10.1128/CVI.00173-07
   PubMed Web of Science ®Google Scholar
• Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, Goudsmit J, Havenga MJ, Kostense S. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003; 41:5046-52; PMID:14605137; https://doi.org/10.1128/JCM.41.11.5046-5052.2003
   PubMed Web of Science ®Google Scholar
• Paris R, Kuschner RA, Binn L, Thomas SJ, Colloca S, Nicosia A, Cortese R, Bailer RT, Sullivan N, Koup RA. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors. Clin Vaccine Immunol 2014; 21:783-6; PMID:24623627; https://doi.org/10.1128/CVI.00011-14
   PubMed Web of Science ®Google Scholar
• Cheng C, Gall JG, Nason M, King CR, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR, et al. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 2010; 84:630-8; PMID:19846512; https://doi.org/10.1128/JVI.00866-09
   PubMed Web of Science ®Google Scholar
• Aste-Amezaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, Patel DK, Dell EC, Franlin LL, Dougherty NM, Bennett PS, et al. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther 2004; 15:293-304; PMID:15018738; https://doi.org/10.1089/104303404322886147
   PubMed Web of Science ®Google Scholar
• Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010; 28:950-7; PMID:19925902; https://doi.org/10.1016/j.vaccine.2009.10.145
   PubMed Web of Science ®Google Scholar
• Kuriyama S, Tominaga K, Kikukawa M, Nakatani T, Tsujinoue H, Yamazaki M, Nagao S, Toyokawa Y, Mitoro A, Fukui H. Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. Anticancer Res 1998; 18:2345-51; PMID:9703877
   PubMed Web of Science ®Google Scholar
• Small JC, Haut LH, Bian A, Ertl HC. The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses. J Leukoc Biol 2014; 96:821-31; PMID:25082150; https://doi.org/10.1189/jlb.1A0813-451RR
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang C, Feng S, Liu C, Li Y, Yang Y, Gao J, Li H, Meng S, Li L, et al. Detection of HPV types and neutralizing antibodies in Gansu province, China. J Med Virol 2009; 81:693-702; PMID:19235880; https://doi.org/10.1002/jmv.21435
   PubMed Web of Science ®Google Scholar
• Chen H, Xiang ZQ, Li Y, Kurupati RK, Jia B, Bian A, Zhou DM, Hutnick N, Yuan S, Gray C, et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol 2010; 84:10522-32; PMID:20686035; https://doi.org/10.1128/JVI.00450-10
   PubMed Web of Science ®Google Scholar
• Nie J, Liu Y, Huang W, Wang Y. Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus. Viruses 2016; 8:107; PMID:27120611; https://doi.org/10.3390/v8040107
   PubMed Web of Science ®Google Scholar
• Ahlborg N, Axelsson B. Dual- and triple-color fluorospot. Methods Mol Biol 2012; 792:77-85. PMID: 21956502
   PubMedGoogle Scholar
• Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther 2010; 17:295-304; PMID:19907498; https://doi.org/10.1038/gt.2009.148
   PubMed Web of Science ®Google Scholar
• Liu Q, Nie J, Huang W, Meng S, Yuan B, Gao D, Xu X, Wang Y. Comparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China. PloS One 2012; 7:e37532; PMID:22655054; https://doi.org/10.1371/journal.pone.0037532
   PubMed Web of Science ®Google Scholar
• Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 2013; 13:421-33; PMID:24279313; https://doi.org/10.2174/1566523213666131125095046
   PubMed Web of Science ®Google Scholar
• Beer SJ, Matthews CB, Stein CS, Ross BD, Hilfinger JM, Davidson BL. Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ther 1998; 5:740-6; PMID:9747453; https://doi.org/10.1038/sj.gt.3300647
   PubMed Web of Science ®Google Scholar
• Chillon M, Lee JH, Fasbender A, Welsh MJ. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther 1998; 5:995-1002; PMID:9813671; https://doi.org/10.1038/sj.gt.3300665
   PubMed Web of Science ®Google Scholar
• Kremer EJ, Boutin S, Chillon M, Danos O. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J Virol 2000; 74:505-12; PMID:10590140; https://doi.org/10.1128/JVI.74.1.505-512.2000
   PubMed Web of Science ®Google Scholar
• Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, Wilson JM, Ertl HC. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002; 76:2667-75; PMID:11861833; https://doi.org/10.1128/JVI.76.6.2667-2675.2002
   PubMed Web of Science ®Google Scholar
• Liu Q, Huang W, Zhang H, Wang Y, Zhao J, Song A, Xie H, Zhao C, Gao D, Wang Y. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther 2014; 21:732-8; PMID:24849042; https://doi.org/10.1038/gt.2014.47
   PubMed Web of Science ®Google Scholar